aprott/iStock by way of Getty Photographs
The European Medicines Company introduced on Friday that its security committee has concluded that Novo Nordisk’s (NVO) (OTCPK:NONOF) fashionable weight reduction/diabetes remedy semaglutide may cause a aspect impact often called non-arteritic anterior ischemic optic neuropathy (NAION) in very uncommon
